Oruka Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Equivalents	46.94	61.58
Short-Term Investments	290.11	314.07
Cash & Short-Term Investments	337.04	375.65
Cash Growth	-10.28%	-
Prepaid Expenses	6.81	1.22
Total Current Assets	343.86	376.87
Property, Plant & Equipment	2.12	1.04
Long-Term Investments	142.54	18.07
Other Long-Term Assets	0.1	0.04
Total Assets	488.62	396.02
Accounts Payable	4.16	3.46
Accrued Expenses	10.6	9.37
Current Portion of Leases	0.62	0.21
Total Current Liabilities	15.37	13.04
Long-Term Leases	1.31	0.76
Total Liabilities	16.69	13.8
Common Stock	0.05	0.04
Additional Paid-In Capital	657.56	463.02
Retained Earnings	-189.16	-83.72
Comprehensive Income & Other	0.55	-0.04
Total Common Equity	469	379.29
Shareholders' Equity	471.93	382.22
Total Liabilities & Equity	488.62	396.02
Total Debt	1.93	0.97
Net Cash (Debt)	477.65	392.75
Net Cash Growth	21.62%	-
Net Cash Per Share	10.47	23.39
Filing Date Shares Outstanding	49.54	37.44
Total Common Shares Outstanding	48.72	37.44
Working Capital	328.48	363.83
Book Value Per Share	9.63	10.13
Tangible Book Value	469	379.29
Tangible Book Value Per Share	9.63	10.13

Source: S&P Capital IQ. Standard template. Financial Sources.